STAMBP Accelerates Progression and Tamoxifen Resistance of Breast Cancer Through Deubiquitinating ERα
Biomolecules · 2025
DOI: 10.3390/biom15111502 ↗Kurz gefasst
Fachartikel in der Zeitschrift Biomolecules, 2025. Verfasst von Zhihuai Wang und 5 weiteren Autor:innen. Beteiligte Einrichtung: Department of General Surgery, The Affiliated Hospital of Guizhou Medical University, Guiyang 550001, China. Hauptthemen laut MEDLINE: Estrogen Receptor alpha, Breast Neoplasms, Tamoxifen, Drug Resistance, Neoplasm. Die Arbeit nennt 35 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: Xihu Qin, the Changzhou “The 14th Five-Year Plan” High-Level Heath Talents Training Project, the Top Talent of Changzhou “The 14th Five-Year Plan” High-Level Heath Talents Training Project.
Abstract (Originalsprache)
Breast cancer (BRCA) remains a global health burden, with endocrine-resistant ER-positive BRCA posing therapeutic challenges. This study investigates STAMBP’s role in breast cancer progression and evaluates its potential as a therapeutic target. Through siRNA library screening in ER-positive cell lines, we identified STAMBP as a key regulator of ERα signaling and observed its upregulation in BRCA samples. (fold changes > 2, sample sizes = 30, p < 0.001), particularly in ER-positive subtypes. Prognostic analysis demonstrated that STAMBP overexpression correlates with poor clinical outcomes in ER-positive BRCA patients (p < 0.05). In vitro functional assays showed STAMBP promoted proliferation, metastasis, and epithelial–mesenchymal transition of ER-positive cells by regulating the activity of ERα signaling. Mechanistically, the deubiquitinase STAMBP directly reduces the K48-linked polyubiquitination levels of ERα, enhancing its protein stability and activating downstream oncogenic signaling. STAMBP knockdown restored tamoxifen sensitivity in endocrine-resistant BRCA cells by reducing ERα stability. This study has certain limitations, including the absence of pharmacological validation and reliance on small, single-center clinical cohorts, which should be addressed in future research to further substantiate the clinical relevance of targeting STAMBP in BRCA. Collectively, our findings identified STAMBP as a prognostic marker and demonstrated its dual role in driving ER-positive BRCA malignancy and mediating endocrine resistance. Targeting STAMBP may represent an innovative approach to improve endocrine therapeutic efficacy in ER-positive BRCA.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Department of General Surgery, The Affiliated Hospital of Guizhou Medical University, Guiyang 550001, China.
- Clinical Medical College, Guizhou Medical University, Guiyang 550001, China.
- Changzhou Medical Center, Nanjing Medical University, Changzhou 213000, China.
- Clinical Medical College, Shandong University, Jinan 250012, China.
ORCID-Profile: Chen Xiong
Förderung
- Xihu Qin
- the Changzhou “The 14th Five-Year Plan” High-Level Heath Talents Training Project
- the Top Talent of Changzhou “The 14th Five-Year Plan” High-Level Heath Talents Training Project
- the Basic Research Project of Changzhou Medical Center of Nanjing Medical University
Zitieren
APA
Wang, Z., Gu, L., Yang, M., Zhou, Y., Qin, X., & Xiong, C. (2025). STAMBP Accelerates Progression and Tamoxifen Resistance of Breast Cancer Through Deubiquitinating ERα. Biomolecules. https://doi.org/10.3390/biom15111502
Vancouver
Wang Z, Gu L, Yang M, Zhou Y, Qin X, Xiong C. STAMBP Accelerates Progression and Tamoxifen Resistance of Breast Cancer Through Deubiquitinating ERα. Biomolecules. 2025. doi:10.3390/biom15111502
BibTeX
@article{Wang2025,
author = {Wang, Zhihuai and Gu, Likai and Yang, Mei and Zhou, Yi and Qin, Xihu and Xiong, Chen},
title = {STAMBP Accelerates Progression and Tamoxifen Resistance of Breast Cancer Through Deubiquitinating ERα},
journal = {Biomolecules},
year = {2025},
doi = {10.3390/biom15111502}
}
EUVIMED